Evolus Inc

EOLS

Company Profile

  • Business description

    Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

  • Contact

    520 Newport Center Drive
    Suite 1200
    Newport BeachCA92660
    USA

    T: +1 949 284-4555

    E: [email protected]

    https://www.evolus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    334

Stocks News & Analysis

stocks

Undervalued ASX share retains wide moat rating despite regulatory pressures

Proposed price regulation impacts our fair value.
stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Tesla: Shares fall as deliveries come in below consensus

Long-term growth less reliant on auto sales.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.702.000.02%
CAC 408,293.57384.834.87%
DAX 4024,119.251,197.665.23%
Dow JONES (US)46,584.4685.42-0.18%
FTSE 10010,673.26324.473.14%
HKSE25,893.02776.493.09%
NASDAQ22,017.8521.510.10%
Nikkei 22556,308.422,878.865.39%
NZX 50 Index13,253.94184.281.41%
S&P 5006,616.855.020.08%
S&P/ASX 2008,951.8021.00-0.23%
SSE Composite Index3,995.00104.832.69%

Market Movers